|
|
Vaccine Detail
|
BCG, Cell Wall Skeleton |
| Vaccine Information |
- Vaccine Name: BCG, Cell Wall Skeleton
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007327
- Type: Live attenuated vaccine
- Status: Licensed
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TNF
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Arabino-mycolates are isolated from BCG-CWS by acid hydrolysis (Miyauchi et al., 2011; Miyauchi et al., 2012)
- Description: A mycobacterial cell wall material and serves as an immunoadjuvant that induces both cell-mediated and humoral immunity. (NCIT_C2339).
This vaccine has been used in research involving bladder cancer. https://ar.iiarjournals.org/content/30/10/4089
|
| Host Response |
|
|
| References |
Miyauchi et al., 2011: Miyauchi M, Murata M, Shibuya K, Koga-Yamakawa E, Uenishi Y, Kusunose N, Sunagawa M, Yano I, Kashiwazaki Y. Arabino-mycolates derived from cell-wall skeleton of Mycobacterium bovis BCG as a prominent structure for recognition by host immunity. Drug discoveries & therapeutics. 2011; 5(3); 130-135. [PubMed: 22466242].
Miyauchi et al., 2012: Miyauchi M, Murata M, Fukushima A, Sato T, Nakagawa M, Fujii T, Koseki N, Chiba N, Kashiwazaki Y. Optimization of cell-wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) emulsion in delayed-type hypersensitivity and antitumor models. Drug discoveries & therapeutics. 2012; 6(4); 218-225. [PubMed: 23006993].
NCIT_C2339: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2339]
|
|
